What drugs are recommended for treating shortness of breath (dyspnea)?

Drugs for Shortness of Breath (SOB)

Opioids, specifically morphine, are the first-line pharmacologic treatment for symptomatic relief of chronic breathlessness, with starting doses of 2.5-5 mg orally every 4 hours for opioid-naïve patients. 1

Treatment Algorithm Based on Clinical Context

For COPD-Related Dyspnea

Initial bronchodilator therapy:

• Start with LAMA/LABA dual therapy (not monotherapy) for patients with moderate-to-high symptoms (mMRC ≥2) and FEV1 <80% predicted 2
• Short-acting β2-agonists with or without short-acting anticholinergics for acute exacerbations 3
• Systemic corticosteroids during exacerbations improve oxygenation and shorten recovery 3

For refractory dyspnea despite optimal bronchodilator therapy:

• Add low-dose oral opioids (morphine 2.5-5 mg every 4 hours) 1
• Titrate upward based on symptom relief, not respiratory rate or blood pressure 4

For Cancer-Related or Palliative Dyspnea

Primary pharmacologic approach:

Opioids (first-line):

• Opioid-naïve patients: Morphine 2.5-5 mg PO every 4 hours OR 1-2.5 mg subcutaneously every 4 hours 1
• Patients already on opioids: Increase current dose by 25-50% OR add 1/6 of total daily opioid dose for breakthrough dyspnea 1, 4, 1
• Alternative opioids: Hydromorphone 1.3 mg PO or 0.2-0.5 mg SC every 4 hours; fentanyl and oxycodone are also effective 4, 1
• Route matters: Oral and parenteral routes are effective; nebulized opioids lack evidence of efficacy 1

Benzodiazepines (adjunctive, especially with anxiety):

• Lorazepam: 0.5-1.0 mg every 6-8 hours PO or sublingual 1
• Midazolam: 2.5-5 mg every 4 hours SC or 10-30 mg/24 hours continuous SC infusion 1
• Use when opioids provide insufficient relief or when anxiety is prominent 4, 1
• Caution: Benzodiazepines alone have small benefit; muscle relaxation may worsen dyspnea in cachectic patients 1

For Excessive Secretions ("Death Rattle")

Antisecretory agents:

• Glycopyrrolate (preferred—doesn't cross blood-brain barrier, lower delirium risk) 4
• Scopolamine (SC or transdermal—note 12-hour onset for patches, not suitable for imminent death) 4
• Atropine or hyoscyamine 4, 1

Cause-Specific Treatments

When underlying etiology is treatable:

• Pleural/abdominal fluid: Therapeutic drainage 4
• Pulmonary embolism: Anticoagulation 4
• Bronchospasm: Bronchodilators 4
• Volume overload: Diuretics 4
• Specific cancer-related causes: Steroids for lymphangitic carcinomatosis, radiation pneumonitis, SVC syndrome, or airway obstruction 1

Critical Dosing Principles

Opioid titration in dying patients:

• Do NOT reduce opioid doses based solely on decreased blood pressure, respiratory rate, or level of consciousness when needed for dyspnea control 4
• Aggressive titration is appropriate for moderate-to-severe symptoms 4
• Clinically significant respiratory depression is uncommon at doses used for dyspnea 5

Renal considerations:

• Avoid morphine in severe renal insufficiency 1
• Adjust all μ-opioid doses and intervals for renal function 1

What NOT to Use

Insufficient evidence or not recommended:

• Nebulized opioids (no proven efficacy over oral/parenteral) 1, 5
• Phenothiazines/neuroleptics (no proven benefit) 1
• Antidepressants or buspirone (unproven) 1
• Methylxanthines in COPD exacerbations (side effects outweigh benefits) 3
• Routine steroids for dyspnea (only for specific indications listed above) 1

Common Pitfalls

• Underdosing opioids due to unfounded fears of respiratory depression—this is rare at therapeutic doses 5
• Using nebulized opioids thinking they have fewer side effects—evidence shows no advantage 1, 5
• Withholding opioids in dying patients based on vital sign changes rather than symptom control 4
• Forgetting constipation prophylaxis when starting opioids—this is the most common side effect 5
• Using transdermal scopolamine for imminent death—12-hour onset makes it inappropriate; use SC route instead 4